BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Corcept Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Corcept Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03604198-399@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT03604198)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2\, Cushing's Syndrome.\nStudy:
  Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant i
 n Patients With Cushing Syndrome\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/relacorilant-lif
 yorli#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03604198
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259317-399@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT07259317)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2.\nStudy: Relacorilant With Na
 b-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenoc
 arcinoma\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07259317
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906341-399@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Relacorilant (Lifyorli): Phase 2 readout est. (NCT06906341)
DESCRIPTION:Relacorilant (Lifyorli)\, phase 2\, Ovarian Cancer.\nStudy: Rel
 acorilant in Combination With Different Treatment Regimens in Patients Wit
 h Gynecological Cancers\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/relacorilant-lifyorli#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0690634
 1
URL:https://assetmemo.bio/drug/relacorilant-lifyorli#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
